The safety of perioperative bevacizumab use;Sécurité d'utilisation du bévacizumab en péri-opératoire

Journal de Chirurgie

Volumn 147, Issue SUPPL.1, 2010, Pages

  Mariani, P ^a  

^a INSTITUT CURIE   (France)

Author keywords

Bevacizumab; Colorectal cancer; Hepatic metastases; Liver surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; COLON TUMOR; COMPARATIVE STUDY; DRUG ANTAGONISM; HUMAN; LIVER RESECTION; LIVER TUMOR; METASTASIS; PATHOLOGY; RECTUM TUMOR; RETROSPECTIVE STUDY; SAFETY; TIME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SAFETY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951124920     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(10)70003-X     Document Type: Article

References (26)

1. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Di Bartolomeo M, et al. Safety and efficacy of first-line bevacizumab with Folfox, Xelox, Folfi ri and fluoropyrimidines in metastatic colorectal cancer: the Beat study. Ann Oncol 2009;20:1842-1847
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
3. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705
4. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712
5. Purdie DM, Berlin JD, Flynn PJ, Grothey A, Kabbinavar FF, Kozloff MF, et al. The safety of long-term bevacizumab use: Results from the Brite observational cohort studt (OCS). J Clin Oncol 2008;26:abstr 4103.
6. Howdieshell TR, Callaway D, Webb WL, Gaines MD, Procter Jr. CD, Sathyanarayana, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 2001;96:173-182
7. Zhang F, Lei MP, Oswald TM, Pang Y, Blain B, Cai ZW, et al. The effect of vascular endothelial growth factor on the healing of ischaemic skin wounds. Br J Plast Surg 2003;56:334-341 (Pubitemid 36927265)
8. Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002;105:43-47
9. LeCouter J, Moritz DR, Li B, Lewis Phillips G, Huan Liang X, Gerber HP, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003;299:890-893
10. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027
11. Van Buren II G, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, et al. The effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 2008;26:1836-1842
12. Redaelli CA, Semela D, Carrick FE, Ledermann M, Candinas D, Sauter B, et al. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 2004;40:305-312
13. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1-7. (Pubitemid 43054046)
14. Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll surg 2006;202:199-200.
15. Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009;145:362-371
16. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90 days mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-2072
17. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-180
18. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, et al. Lack of evidence for increased operative morbidity after hepatectomy with peri-operative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007;14:759-765
19. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE et al. Addition of bevacizumab to irinotecan-and oxaliplatinbased preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008;206:96-106.
20. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, et al. Preoperative bevacizumab does not signifi cantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008;26:5254-5260
21. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:1830-1835
22. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008;15:2765-2772
23. Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009;16:1553-1559
24. Grothey A, Sugrue M, Hedrick E, Purdie D, Yi J, Dong W, et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25:abstr 4036.
25. Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Steis R, et al. Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRITE). 31st ESMO Congress, Istambul, 2006. Ann Oncol 2006;17:ix128 (abstract 375P).
26. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a metaanalysis. Lancet Oncol 2009;10:559-568